Life Biosciences vs Earendil Labs
Side-by-side comparison of AI visibility scores, market position, and capabilities
Closed $80M Series D (Apr 2026). FDA-cleared IND for ER-100 in optic neuropathies (Jan 2026). Phase 1 enrolling. Co-founded by Harvard's David Sinclair.
About
Life Biosciences is running the first FDA-cleared human trial of partial epigenetic reprogramming, using gene therapy to reverse vision loss caused by aging. Co-founded by Harvard aging biologist David Sinclair — whose research showed that aged retinal cells could be restored to youthful function by expressing Yamanaka factors — Life Biosciences received FDA clearance for its IND (Investigational New Drug) for ER-100 in optic neuropathies in January 2026 and closed an $80 million Series D in April 2026.
Full-stack AI biologics company raised $787M in Mar 2026 backed by Sanofi, Pfizer/Hillhouse, and DST Global; $2.56B Sanofi collaboration signed Jan 2026; platform generates 40+ AI-designed protein therapeutics across multiple therapeutic areas.
About
Earendil Labs is a full-stack AI biologics company that uses a proprietary AI platform to design protein therapeutics at scale. The company secured $787 million in financing in March 2026, backed by Sanofi, the Pfizer-Hillhouse Biotech Fund, Dimension Capital, and DST Global — one of the largest AI drug discovery raises in the industry's history.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.